Product
Toripalimab + Bevacizumab
1 clinical trial
1 indication
Indication
Hepatocellular carcinomaClinical trial
A Randomized, Open-label, Multi-center Phase III Clinical Study to Evaluate the Safety and Efficacy of Toripalimab (JS001) Combined With Bevacizumab Versus Sorafenib as First-line Therapy for Advanced Hepatocellular CarcinomaStatus: Active (not recruiting), Estimated PCD: 2023-10-31